The clinical trials for the Her2-targeted PET imaging agent is scheduled to begin later in 2012.

Future clinical trials will determine if Her 2 status changes over time, monitor therapy of patients with metastatic breast cancer receiving anti-Her2 treatments, and help resolve indeterminate Her2 tests.

The studies, if resulted positive, will help the companies to develop better targeting anti-Her2 therapies to those patients may most likely to benefit.

GE Healthcare medical diagnostics research head Marivi Mendizabal said, "We expect a productive collaboration with leading academics and the pharma industry to help this research reach its full potential."

Affibody CEO David Bejker said, "Our clinical data, the first of which was presented at the 34th San Antonio Breast Cancer Symposium last December, is the result of collaborative research with leading academics and has led us to believe that a Her2-targeted PET imaging agent may benefit many cancer patients."